NEWS TIPS & FEATURES

Rituxan Improves Survival in Young Adults with Acute Lymphoblastic Leukemia

Acccording to results recently published in the New England Journal of Medicine, young adults with CD20-positive, Philadelphia chromosome  (PH)-negative acute lymphoblastic leukemia (ALL), experience... [...]


National Ovarian Cancer Coalition Launches CancerConnect Social Media Platform for Women with Ovarian Cancer

Austin TX/Sun Valley ID–The National Ovarian Cancer Coalition (NOCC) now offers a specialized social network for women with ovarian cancer. The NOCC CancerConnect Community offers these women a safe,... [...]


CDC Vaccine Information and Recommendations for the 2016/17 Influenza Season

With the start of a new school year and the approaching winter, it’s time to get informed about the most critical information regarding the 2016/17 influenza vaccines and CDC’s vaccination recommendations. The... [...]


140723-dang-026

Have a Question about Metastatic Breast Cancer? Ask the Expert!

Join us on October 10th! October 10th, 6:00-7:00 PM, EST Tune in here. Join us for a live Ask the Expert session with Memorial Sloan Kettering Cancer Center’s Chau T. Dang, MD. She will discuss advances... [...]


Cotellic®/Zelboraf® Combo: New Standard of Care for Melanoma

The treatment combination consisting of Cotellic® (cobimetinib) plus Zelboraf® (vemurafenib) improves overall survival for patients with advanced, BRAF (V600) mutation-positive melanoma. These confirmatory... [...]


Pass it On: It’s National Ovarian Cancer Awareness Month

In 2016, the American Cancer Association estimates that 22,280 women will be diagnosed with ovarian cancer, and 14,240 women will die from the disease. The incidence of ovarian cancer has decreased slightly... [...]


Announcing the CancerConnect Head and Neck Cancer Support Community

Your story matters. Head and neck cancer is a challenging diagnosis, connecting with others who have had to deal with the side effects of treatment and the challenges of treatment decision making is an... [...]


FDA Grants Breakthrough Therapy Designation to Keytruda® for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Keytruda® (pembrolizumab) for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). The... [...]


Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer

Whole-brain radiotherapy (WBRT) provides “little additional clinically significant benefit” for patients with non–small cell lung cancer (NSCLC) with brain metastases, according to doctors... [...]


« More News Tips & Features

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS